An 11-bp duplication in the promoter region of the VHL gene in a patient with cerebellar hemangioblastoma and renal oncocytoma

被引:6
作者
Muscarella, Lucia Anna [1 ]
Barbano, Raffaela [1 ]
Augello, Bartolomeo [1 ]
Formica, Vincenza [1 ]
Micale, Lucia [1 ]
Zelante, Leopoldo [1 ]
D'Agruma, Leonardo [1 ]
Merla, Giuseppe [1 ]
机构
[1] IRCCS Casa Sollievo Sofferenza, Serv Genet Med, I-71013 San Giovanni Rotondo, Italy
关键词
von Hippel Lindau; hemangioblastomas; allelic imbalance; qPCR; EMSA;
D O I
10.1007/s10038-007-0138-1
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Central nervous system hemangioblastomas are benign vascular tumours that may present sporadically or as manifestation of the von Hippel-Lindau (VHL) disease. VHL Syndrome is a rare autosomal dominant disorder characterized, besides hemangioblastomas, by susceptibility to multifocal and bilateral renal cell carcinoma and cysts, retinal angiomas, pheochromocytoma, epididymis cystoadenoma, pancreatic cysts and/or islet cell tumours. Germline mutations of VHL tumour suppressor gene cause the VHL disease, while somatic mutations have been associated with sporadic hemangioblastomas and clear-cell renal carcinomas. We identified an 11-bp duplication in the promoter region of the VHL gene in a VHL-affected individual. Functional analysis revealed that this variant affects the binding or the binding affinity of one or more transcription factors that regulate the transcription of VHL in vivo, reducing the endogenous levels of VHL mRNA. Moreover, consistent with the "two hits" model, microsatellite analysis of hemangioblastoma tissue from this patient revealed Allelic Imbalance for the chromosomal region near the VHL gene. We propose that these molecular events, through a loss of pVHL function, lead to the onset of the VHL-related tumours in that individual.
引用
收藏
页码:485 / 491
页数:7
相关论文
共 40 条
[21]  
LINEHAN M, 2001, RENAL CARCINOMA, P907
[22]  
LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564
[23]   Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method [J].
Livak, KJ ;
Schmittgen, TD .
METHODS, 2001, 25 (04) :402-408
[24]   A genetic register for von Hippel-Lindau disease [J].
Maddock, IR ;
Moran, A ;
Maher, ER ;
Teare, MD ;
Norman, A ;
Payne, SJ ;
Whitehouse, R ;
Dodd, C ;
Lavin, M ;
Hartley, N ;
Super, M ;
Evans, DGR .
JOURNAL OF MEDICAL GENETICS, 1996, 33 (02) :120-127
[25]   von Hippel-Lindau disease [J].
Maher, ER ;
Kaelin, WG .
MEDICINE, 1997, 76 (06) :381-391
[26]   Endolymphatic sac tumors - A source of morbid hearing loss in von Hippel-Lindau disease [J].
Manski, TJ ;
Heffner, DK ;
Glenn, GM ;
Patronas, NJ ;
Pikus, AT ;
Katz, D ;
Lebovics, R ;
Sledjeski, K ;
Choyke, PL ;
Zbar, B ;
Linehan, WM ;
Oldfield, EH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (18) :1461-1466
[27]  
MARTELLA M, 2006, MOL ANAL 2 UNCHARACT
[28]  
Prowse AH, 1997, AM J HUM GENET, V60, P765
[29]   Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis [J].
Richards, FM ;
Schofield, PN ;
Fleming, S ;
Maher, ER .
HUMAN MOLECULAR GENETICS, 1996, 5 (05) :639-644
[30]   Evaluation of loss of heterozygosity/allelic imbalance scoring in tumor DNA [J].
Skotheim, RI ;
Diep, CB ;
Kraggerud, SM ;
Jakobsen, KS ;
Lothe, RA .
CANCER GENETICS AND CYTOGENETICS, 2001, 127 (01) :64-70